依洛尤单抗在颈动脉易损斑块治疗中的价值分析OA

Objective To evaluate the therapeutic value of evolocumab in the treatment of vulnerable carotid plaques.Methods A total of 90 patients with vulnerable carotid plaques complicated by hypercholesterolemia who were admitted to Wuxi Second People's Hospital from April 2022 to April 2024 were enrolled and randomly assigned to an observation group(n=45)or a control group(n=45).Both groups received guideline-directed lipid-lowering therapy;in addition.the observation group was treated with evolocumab injection.Both groups received regular treatment for 6 months.Lipid profiles.vulnerable carotid plaque-related indices.and adverse events were compared between the two groups before and after treatment.Results After treatment.levels of low-density lipoprotein cholesterol(LDL-C).total cholesterol(TC).and high-sensitivity C-reactive protein(hs-CRP)decreased in both groups compared with those before treatment;these levels were lower in the observation group than in the control group.and the differences were statistically significant(P＜0.05).Triglyceride(TG)levels decreased in the observation group after treatment and were lower than those in the control group at the same time point.with statistically significant differences(P＜0.05).There were no statistically significant differences in high-density lipoprotein cholesterol(HDL-C)levels within or between the two groups before and after treatment(P＞0.05).The LDL-C goal attainment rate was higher in the observation group than in the control group.with a statistically significant difference(P＜0.05).After treatment.carotid intima-media thickness(IMT).plaque area.and plaque thickness were significantly lower in both groups than those before treatment;these indices were lower in the observation group than in the control group.and the differences were statistically significant(P＜0.05).There were no statistically significant differences in the number of plaques within or between the two groups before and after treatment(P＞0.05).After treatment.the distribution of plaque types differed significantly between the two groups(P＜0.05).The incidence of drug-related adverse reactions during treatment did not differ significantly between the two groups(P＞0.05).Conclusion On the basis of conventional statin therapy.the addition of evolocumab can effectively reverse carotid atherosclerosis and improve the stability of vulnerable plaques.representing a potentially beneficial treatment strategy to reduce the risk of vulnerable carotid plaque rupture.